NIH Rejects Compulsory License For Abbott's Norvir

Law360, New York (August 5, 2004, 12:00 AM EDT) -- A U.S. government agency has rejected calls for a compulsory license for a popular HIV medicine used to boost AIDS drugs, dealing a setback for activists who had hoped to use a little-known law to override a drug maker’s patent rights.

In its ruling, the National Institutes of Health rejected a "march-in petition" filed by Essential Inventions, which urged the NIH to claim control over patent rights to Norvir, a drug sold by Abbott Laboratories. The group asked the NIH to act after Abbott raised the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.